The Go-to-Market Slide

Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing.

The Go-to-Market slide is important for seed-stage companies pitching for funding.

It shows how the startup will enter the market.

Consider setting up an initial target market.

List the top twenty customers who will buy your product and gather them into a group called the beachhead market.

This shows a focused strategy with a predetermined list of companies to pursue.

Show how these companies are a great fit for your product.

Then mention that you have already talked with all of them and they are interested in buying.

Next, show how these companies will lead to more and bigger companies in the market.

Avoid the percent of market approach in which 1% of a billion-dollar market is a big number.

This fails with investors as it doesn't indicate what customers you are going to pursue.

It demonstrates a lack of understanding of the market.

Focus on identifying the customers and their segment and show how you have already sold to them.

Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding.

Let's go startup something today.

_______________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https://tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.

Alternatives to an MVP

Hello, this is Hall T. Martin with the Startup Funding Espresso -- your daily shot of startup funding and investing.

Building a full-blown product is unwise at the early stage, as the startup will inevitably build the wrong thing.

It's best to test the market first.

Minimum viable products or MVPs are a better solution than a product, as it's cheaper and easier to do.

The goal of the MVP is to generate a dialogue with customers and estimate demand.

There are alternatives to building an MVP.

Here are some examples:

Create a datasheet showing the product you intend to build and sell.

Show the features and benefits of it.

Use this to spark a dialog with customers.

In-person interviews work best so as to gauge interest and capture feedback.

This can be especially useful in setting the initial price for the product.

Another alternative is to create a website landing page with key information.

Then drive traffic to it.

This will demonstrate how interested or disinterested the target market is in the proposed product.

Set up the landing page to take orders for the product to see how many actually sign up.

Tweak the content till you have interest in the product.

Pretend you have the proposed product available today and try to sell it.

This will inform your decision about what to build and is far cheaper than an MVP.

Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding.

Let's go startup something today.

_______________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https://tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.

In this episode of Investor Connect, we hear from Randy Hubbell, CEO of Soliris Endovascular, a medical device company developing peripheral endovascular technologies for PAD and dialysis access. Randy outlines the company's two advanced programs: Soliris SX, a self-expanding covered stent approved in 45 countries with over 15,000 sold and about $5M in recurring revenue, and a breakthrough-designated drug-eluting version that adds sirolimus to the stent edges to address edge restenosis.

He shares Phase 2 interim results from a 115-patient study showing 95% patency compared to 70–75% for covered stents and about half failing after balloon angioplasty, with imaging consistent out to 12 months. Randy explains Soliris' tuck-in acquisition strategy aimed at multinationals, updates investors on a $5M bridge round and an upcoming $25M Series A to fund a single pivotal study and PMA toward a projected $550–$600M exit, followed by Q&A on Anvisa, global distribution, and strategic acquirer interest.

________________________________________________________________________

For more episodes from Investor Connect, please visit the site at: http://investorconnect.org

Check out our other podcasts here: https://investorconnect.org/
For Investors check out: https://tencapital.group/investor-landing/
For Startups check out: https://tencapital.group/company-landing/
For eGuides check out: https:/_/tencapital.group/education/
For upcoming Events, check out https://tencapital.group/events/

For Feedback please contact info@tencapital.group

Please follow, share, and leave a review.

Music courtesy of Bensound.